Vanguard Group Inc. Has $257.86 Million Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Vanguard Group Inc. boosted its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 3.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,233,168 shares of the biopharmaceutical company's stock after buying an additional 214,666 shares during the period. Vanguard Group Inc. owned 8.81% of Ultragenyx Pharmaceutical worth $257,862,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in RARE. Sands Capital Management LLC acquired a new position in shares of Ultragenyx Pharmaceutical during the second quarter valued at $123,335,000. Norges Bank acquired a new position in shares of Ultragenyx Pharmaceutical during the fourth quarter valued at $33,526,000. BlackRock Inc. increased its holdings in shares of Ultragenyx Pharmaceutical by 12.4% during the first quarter. BlackRock Inc. now owns 4,873,356 shares of the biopharmaceutical company's stock valued at $195,422,000 after purchasing an additional 536,513 shares during the period. State Street Corp increased its holdings in shares of Ultragenyx Pharmaceutical by 26.1% during the second quarter. State Street Corp now owns 2,457,308 shares of the biopharmaceutical company's stock valued at $146,603,000 after purchasing an additional 508,624 shares during the period. Finally, Wellington Management Group LLP boosted its stake in Ultragenyx Pharmaceutical by 17.1% during the first quarter. Wellington Management Group LLP now owns 3,370,245 shares of the biopharmaceutical company's stock valued at $244,747,000 after buying an additional 492,842 shares in the last quarter. 97.67% of the stock is owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical Price Performance

Ultragenyx Pharmaceutical stock traded down $0.13 during mid-day trading on Friday, hitting $46.69. The company's stock had a trading volume of 543,698 shares, compared to its average volume of 683,847. The firm's 50 day moving average is $47.40 and its 200 day moving average is $42.49. The company has a market cap of $3.84 billion, a PE ratio of -5.61 and a beta of 0.66. Ultragenyx Pharmaceutical Inc. has a 52-week low of $31.52 and a 52-week high of $54.98.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported ($1.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.65) by $0.13. Ultragenyx Pharmaceutical had a negative return on equity of 369.54% and a negative net margin of 139.70%. The firm had revenue of $127.39 million during the quarter, compared to the consensus estimate of $119.38 million. During the same period in the prior year, the business earned ($2.16) EPS. The business's revenue for the quarter was up 23.3% on a year-over-year basis. As a group, analysts forecast that Ultragenyx Pharmaceutical Inc. will post -6.34 EPS for the current year.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, EVP Thomas Richard Kassberg sold 11,509 shares of the firm's stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $49.93, for a total transaction of $574,644.37. Following the completion of the sale, the executive vice president now directly owns 252,823 shares of the company's stock, valued at approximately $12,623,452.39. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Matthew K. Fust sold 12,195 shares of the firm's stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $50.88, for a total value of $620,481.60. Following the transaction, the director now directly owns 14,860 shares of the company's stock, valued at approximately $756,076.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Thomas Richard Kassberg sold 11,509 shares of the firm's stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $49.93, for a total value of $574,644.37. Following the completion of the transaction, the executive vice president now directly owns 252,823 shares in the company, valued at $12,623,452.39. The disclosure for this sale can be found here. Insiders sold 31,974 shares of company stock valued at $1,639,721 in the last three months. Corporate insiders own 6.80% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on RARE shares. Wells Fargo & Company assumed coverage on Ultragenyx Pharmaceutical in a research note on Friday, December 8th. They set an "overweight" rating and a $72.00 target price for the company. Canaccord Genuity Group increased their price target on Ultragenyx Pharmaceutical from $110.00 to $111.00 and gave the company a "buy" rating in a research report on Wednesday, February 21st. Cantor Fitzgerald reiterated an "overweight" rating and issued a $107.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, February 27th. Wedbush increased their price target on Ultragenyx Pharmaceutical from $47.00 to $48.00 and gave the company a "neutral" rating in a research report on Friday, February 16th. Finally, StockNews.com upgraded Ultragenyx Pharmaceutical from a "sell" rating to a "hold" rating in a research report on Friday, December 8th. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, Ultragenyx Pharmaceutical has a consensus rating of "Moderate Buy" and an average price target of $91.55.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.